- Home
- GRNQ vs IBIO Comparison
GRNQ vs IBIO Comparison
Compare GRNQ & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNQ
- IBIO
- Stock Information
- Founded
- GRNQ 2013
- IBIO 2008
- Country
- GRNQ Malaysia
- IBIO United States
- Employees
- GRNQ N/A
- IBIO N/A
- Industry
- GRNQ EDP Services
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- GRNQ Technology
- IBIO Health Care
- Exchange
- GRNQ Nasdaq
- IBIO Nasdaq
- Market Cap
- GRNQ 13.3M
- IBIO 15.9M
- IPO Year
- GRNQ 2018
- IBIO N/A
- Fundamental
- Price
- GRNQ $1.54
- IBIO $0.71
- Analyst Decision
- GRNQ
- IBIO Strong Buy
- Analyst Count
- GRNQ 0
- IBIO 3
- Target Price
- GRNQ N/A
- IBIO $4.87
- AVG Volume (30 Days)
- GRNQ 85.5K
- IBIO 5.3M
- Earning Date
- GRNQ 08-12-2025
- IBIO 05-02-2025
- Dividend Yield
- GRNQ N/A
- IBIO N/A
- EPS Growth
- GRNQ N/A
- IBIO N/A
- EPS
- GRNQ N/A
- IBIO N/A
- Revenue
- GRNQ $3,190,761.00
- IBIO $375,000.00
- Revenue This Year
- GRNQ N/A
- IBIO $36.00
- Revenue Next Year
- GRNQ N/A
- IBIO N/A
- P/E Ratio
- GRNQ N/A
- IBIO N/A
- Revenue Growth
- GRNQ N/A
- IBIO 650.00
- 52 Week Low
- GRNQ $0.80
- IBIO $0.64
- 52 Week High
- GRNQ $2.24
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- GRNQ 56.94
- IBIO 37.70
- Support Level
- GRNQ $1.47
- IBIO $0.68
- Resistance Level
- GRNQ $1.70
- IBIO $1.04
- Average True Range (ATR)
- GRNQ 0.18
- IBIO 0.12
- MACD
- GRNQ -0.01
- IBIO -0.00
- Stochastic Oscillator
- GRNQ 48.19
- IBIO 7.89
About GRNQ Greenpro Capital Corp.
Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.